VUNO’s AI electrocardiogram analysis software, VUNO Med DeepECG UniV, simultaneously received European CE MDR and UK UKCA certifications in February. The product integrates solutions for analyzing four or more conditions, including acute myocardial infarction, enabling entry into
2026-05-15
Seoul Pharmaceutical has signed 5-year supply contracts worth a total of 1.424 billion won with China and the UAE for Bultium, an ODF erectile dysfunction treatment. The counterparties are China’s Medifines, under a 644 million won contract, and the UAE’s Paramedica, under a 780
2026-05-15
NGeneBio reported first-quarter revenue of 11.95 billion won following its absorption merger with NGene Pharma, a 500% increase from the same period a year earlier. The company also completed research-use development of a diagnostic panel for detecting measurable residual disease
2026-05-15
JLK has obtained a total of 78 regulatory approvals for its AI medical solutions worldwide, including eight from the US Food and Drug Administration and eight from Japan’s Pharmaceuticals and Medical Devices Agency. Its flagship product, MEDIHUB STROKE, comprises 12 stroke soluti
2026-05-15
Dongwha Pharm has applied for marketing approval for DW6017, a P-CAB-class treatment for gastroesophageal reflux disease in a market worth 700 billion won. The drug recently demonstrated equivalence to the reference product in a bioequivalence study. If approved, it is expected t
2026-05-15
HLB Panagene invested 1.1 billion won, or 35% of its first-quarter revenue, to begin developing next-generation drugs known as AOCs. The PNA-based AOCs aim to treat difficult-to-treat diseases, including Duchenne muscular dystrophy (DMD), by improving on the toxicity profile of e
2026-05-15
Samch당 Pharmaceutical has licensed its oral diabetes and obesity treatment, semaglutide, to the US for $100 million (approximately 145 billion won), securing 90% of the net profit. The agreement will remain in effect for 10 years and follows a 30 million euro agreement with 11 Eu
2026-05-15
MediPost’s knee osteoarthritis treatment Cartistem achieved statistical significance for both the primary and secondary endpoints in a Japanese phase 3 clinical trial, announcing successful results in May 2026. The trial enrolled patients with knee osteoarthritis classified as K&
2026-05-15
Biosolution received approval in January for the Australian investigational new drug (IND) application for its allogeneic cartilage cell therapy Cartiroid and is moving to target South Korea’s knee osteoarthritis market, valued at approximately 1.77 trillion won. Cartiroid is a t
2026-05-15
Ildong Pharmaceutical is conducting a domestic phase 3 trial of fadoprazan, a novel drug targeting the 370 billion won P-CAB market, with patent protection secured through 2046. The drug demonstrated noninferiority to standard treatment in a phase 2 trial and is currently being d
2026-05-15
